Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025
Madrigal Pharmaceuticals (NASDAQ: MDGL) will release its third-quarter 2025 financial results on Tuesday, November 4, 2025 prior to the open of U.S. markets. Management will host a live webcast at 8:00 a.m. Eastern Time the same day to review financial and operating results.
Investors can access the live webcast via the company’s Investor Relations website and are advised to register at least 15 minutes before the start time. A replay will be available approximately two hours after the live webcast.
Madrigal Pharmaceuticals (NASDAQ: MDGL) annuncerà i propri risultati finanziari del terzo trimestre 2025 il martedì 4 novembre 2025 prima dell'apertura dei mercati statunitensi. La direzione terrà un webcast in diretta alle 8:00 ora della costa orientale (ET) nello stesso giorno per rivedere i risultati finanziari e operativi.
Gli investitori possono accedere al webcast in diretta tramite il sito della società Investor Relations e si consiglia di registrarsi almeno 15 minuti prima dell'inizio. Una replica sarà disponibile circa due ore dopo il webcast in diretta.
Madrigal Pharmaceuticals (NASDAQ: MDGL) divulgará sus resultados financieros del tercer trimestre de 2025 el martes, 4 de noviembre de 2025, antes de la apertura de los mercados de EE. UU. La dirección ejecutiva realizará una transmisión en directo a las 8:00 a. m. hora del Este (ET) el mismo día para revisar los resultados financieros y operativos.
Los inversionistas pueden acceder a la transmisión en directo a través del sitio de Investor Relations de la empresa y se recomienda registrarse al menos 15 minutos antes de la hora de inicio. Una réplica estará disponible aproximadamente dos horas después de la transmisión en directo.
Madrigal Pharmaceuticals (NASDAQ: MDGL) 은 미국 시장 개장 전에 2025년 3분기 재무 실적을 발표합니다. 경영진은 같은 날 동부 표준시 오전 8:00에 라이브 웹캐스트를 진행하여 재무 및 운영 실적을 검토합니다.
투자자들은 회사의 Investor Relations 웹사이트를 통해 라이브 웹캐스트에 접속할 수 있으며 시작 15분 전까지 등록하는 것이 좋습니다. 라이브 웹캐스트 이후 약 두 시간 후에 재방송이 제공됩니다.
Madrigal Pharmaceuticals (NASDAQ: MDGL) publiera ses résultats financiers du troisième trimestre 2025 le mardi 4 novembre 2025, avant l’ouverture des marchés américains. La direction organisera une webdiffusion en direct à 8h00, heure de l’Est le même jour pour examiner les résultats financiers et opérationnels.
Les investisseurs peuvent accéder à la webdiffusion en direct via le site des Relations investisseurs de l’entreprise et il est conseillé de s’inscrire au moins 15 minutes avant l’heure de début. Une rediffusion sera disponible environ deux heures après la webdiffusion.
Madrigal Pharmaceuticals (NASDAQ: MDGL) wird am Dienstag, dem 4. November 2025 vor der Öffnung der US-Märkte die Ergebnisse zum dritten Quartal 2025 veröffentlichen. Das Management wird am selben Tag um 8:00 Uhr Eastern Time eine Live-Webcast durchführen, um Finanz- und Betriebsergebnisse zu überprüfen.
Investoren können über die Investor Relations-Website des Unternehmens auf den Live-Webcast zugreifen und sollten sich mindestens 15 Minuten vor dem Start registrieren. Eine Wiedergabe wird ungefähr zwei Stunden nach dem Live-Webcast verfügbar sein.
مادريغال للأدوية (ش.م.ع NASDAQ: MDGL) ستعلن عن نتائجها المالية للربع الثالث من عام 2025 في يوم الثلاثاء 4 نوفمبر 2025 قبل افتتاح الأسواق الأمريكية. ستستضيف الإدارة بثاً مباشراً عبر الويب في الساعة 8:00 صباحاً بتوقيت شرق الولايات المتحدة في اليوم نفسه لمراجعة النتائج المالية والتشغيلية.
يمكن للمستثمرين الوصول إلى البث المباشر عبر موقع علاقات المستثمرين للشركة ويُنصح بالتسجيل قبل 15 دقيقة على الأقل من البدء. سيكون هناك إعادة بث متاحة تقريباً بعد ساعتين من البث المباشر.
Madrigal Pharmaceuticals（NASDAQ: MDGL） 将于美国市场开盘前公布其2025 年第三季度财务业绩。管理层将在同日美国东部时间上午 8:00举行现场直播网络直播，以汇总财务和运营业绩。
投资者可通过公司的投资者关系网站访问现场直播，并建议在开始时间前至少注册 15 分钟。现场直播大约在实时广播结束后两小时提供回放。
- None.
- None.
CONSHOHOCKEN, Pa., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its third-quarter 2025 financial results on Tuesday, Nov. 4, 2025, prior to the open of the U.S. financial markets.
Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.
The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
The webcast will be available approximately two hours after the live webcast.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
When will Madrigal Pharmaceuticals (MDGL) release Q3 2025 results?
What time is the Madrigal (MDGL) Q3 2025 webcast on November 4, 2025?
How can investors access the Madrigal (MDGL) Q3 2025 webcast?
Will Madrigal (MDGL) provide a replay of the November 4, 2025 webcast?
Is Madrigal (MDGL) presenting financial results before or after U.S. market open on Nov 4, 2025?
